Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pituitary Gland, Posterior | 10 | 2014 | 17 | 3.240 |
Why?
|
| Calcium | 7 | 2014 | 588 | 1.280 |
Why?
|
| Presynaptic Terminals | 5 | 2014 | 38 | 1.240 |
Why?
|
| Arginine Vasopressin | 5 | 2014 | 22 | 0.990 |
Why?
|
| Receptors, Opioid, mu | 3 | 2014 | 13 | 0.840 |
Why?
|
| Oxytocin | 4 | 2012 | 45 | 0.810 |
Why?
|
| Calcium Channels, N-Type | 2 | 2012 | 11 | 0.690 |
Why?
|
| Neuropeptides | 2 | 2014 | 83 | 0.660 |
Why?
|
| Nerve Endings | 2 | 2012 | 8 | 0.660 |
Why?
|
| Vasopressins | 2 | 2012 | 16 | 0.650 |
Why?
|
| Synapses | 2 | 2010 | 193 | 0.580 |
Why?
|
| Rats | 9 | 2015 | 2014 | 0.510 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2014 | 629 | 0.490 |
Why?
|
| Ethanol | 3 | 2015 | 331 | 0.480 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 2 | 2014 | 45 | 0.480 |
Why?
|
| Action Potentials | 3 | 2012 | 112 | 0.480 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 2 | 2015 | 31 | 0.480 |
Why?
|
| Exocytosis | 3 | 2014 | 61 | 0.470 |
Why?
|
| Calcium Channels, L-Type | 2 | 2013 | 26 | 0.460 |
Why?
|
| Magnesium | 1 | 2015 | 56 | 0.450 |
Why?
|
| Secretory Vesicles | 1 | 2014 | 23 | 0.430 |
Why?
|
| Ryanodine | 1 | 2014 | 10 | 0.420 |
Why?
|
| Intracellular Membranes | 1 | 2014 | 50 | 0.420 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2014 | 9 | 0.420 |
Why?
|
| Ion Channel Gating | 1 | 2014 | 45 | 0.420 |
Why?
|
| Neurosecretion | 1 | 2012 | 2 | 0.370 |
Why?
|
| Analgesics, Opioid | 3 | 2014 | 551 | 0.350 |
Why?
|
| Patch-Clamp Techniques | 6 | 2013 | 133 | 0.350 |
Why?
|
| Adenosine Triphosphate | 2 | 2014 | 299 | 0.350 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2010 | 8 | 0.330 |
Why?
|
| Calcium Channels | 1 | 2010 | 104 | 0.320 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 3 | 2014 | 3 | 0.270 |
Why?
|
| Animals | 13 | 2015 | 21500 | 0.260 |
Why?
|
| Neurochemistry | 1 | 2007 | 2 | 0.260 |
Why?
|
| Biological Assay | 1 | 2007 | 59 | 0.250 |
Why?
|
| Calcium Signaling | 3 | 2014 | 165 | 0.230 |
Why?
|
| Neurons | 2 | 2009 | 950 | 0.210 |
Why?
|
| Synaptic Transmission | 3 | 2010 | 152 | 0.210 |
Why?
|
| Membrane Potentials | 2 | 2014 | 141 | 0.180 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2209 | 0.170 |
Why?
|
| Drug Tolerance | 2 | 2013 | 33 | 0.150 |
Why?
|
| Chromaffin Cells | 2 | 2009 | 7 | 0.140 |
Why?
|
| Male | 8 | 2014 | 31137 | 0.130 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2013 | 88 | 0.120 |
Why?
|
| Purinergic P2X Receptor Agonists | 1 | 2014 | 1 | 0.110 |
Why?
|
| Purinergic P2X Receptor Antagonists | 1 | 2014 | 7 | 0.110 |
Why?
|
| Cytoplasm | 1 | 2015 | 285 | 0.100 |
Why?
|
| Hippocampus | 1 | 2015 | 280 | 0.100 |
Why?
|
| In Vitro Techniques | 2 | 2013 | 495 | 0.100 |
Why?
|
| Steroids | 1 | 2013 | 58 | 0.100 |
Why?
|
| Central Nervous System Depressants | 1 | 2013 | 46 | 0.090 |
Why?
|
| Receptor Cross-Talk | 1 | 2012 | 10 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 881 | 0.090 |
Why?
|
| Feedback, Physiological | 1 | 2012 | 60 | 0.090 |
Why?
|
| Cholesterol | 1 | 2013 | 261 | 0.090 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 1 | 2010 | 1 | 0.080 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2010 | 37 | 0.080 |
Why?
|
| GTP-Binding Proteins | 1 | 2010 | 88 | 0.080 |
Why?
|
| Electric Capacitance | 1 | 2009 | 3 | 0.080 |
Why?
|
| Mice | 3 | 2014 | 11193 | 0.070 |
Why?
|
| Mitochondria | 1 | 2013 | 403 | 0.070 |
Why?
|
| Dopamine | 1 | 2009 | 108 | 0.070 |
Why?
|
| Receptors, Purinergic P2X2 | 1 | 2008 | 1 | 0.070 |
Why?
|
| Suramin | 1 | 2008 | 2 | 0.070 |
Why?
|
| Pyridoxal Phosphate | 1 | 2008 | 2 | 0.070 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2008 | 9 | 0.070 |
Why?
|
| Receptors, Purinergic P2X3 | 1 | 2008 | 5 | 0.070 |
Why?
|
| Time Factors | 2 | 2014 | 3782 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 905 | 0.070 |
Why?
|
| Supraoptic Nucleus | 1 | 2007 | 2 | 0.070 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2007 | 20 | 0.070 |
Why?
|
| Neural Pathways | 1 | 2007 | 103 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2008 | 236 | 0.060 |
Why?
|
| Synaptic Vesicles | 1 | 2005 | 25 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 460 | 0.060 |
Why?
|
| Membrane Microdomains | 1 | 2005 | 50 | 0.060 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2004 | 15 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 683 | 0.050 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 1 | 2013 | 4 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2013 | 90 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2013 | 94 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 78 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2013 | 145 | 0.020 |
Why?
|
| Cell Communication | 1 | 2013 | 135 | 0.020 |
Why?
|
| Biological Transport | 1 | 2013 | 294 | 0.020 |
Why?
|
| Humans | 2 | 2013 | 65676 | 0.020 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2004 | 4 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 2004 | 70 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2004 | 144 | 0.010 |
Why?
|
| Alcoholism | 1 | 2004 | 329 | 0.010 |
Why?
|